LLY vs SRPT

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Sarepta's 10x growth potential remains highly challenged by persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance ($1.2B-$1.4B from $1.86B in 2025). While recent initial Phase 1/2 siRNA data shows promise for future pipeline diversification and an sNDA for traditional approval of existing PMOs is planned, these bright...